ACA
PACB icon

Ascension Capital Advisors’s Pacific Biosciences PACB Stock Holding History

Ascension Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,800
Closed -$132K – 37
2023
Q3 		$132K Buy
+15,800
New +$181K 0.08% 38

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ascension Capital Advisors's PACB Position: Q4 2023 in Review

Ascension Capital Advisors sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 15,800 shares — an estimated $132K sold.

Ascension Capital Advisors first reported a position in PACB in Q3 2023 and held it in 1 quarter. The position peaked at $132K in Q3 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Ascension Capital Advisors reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Ascension Capital Advisors sold 15,800 Pacific Biosciences shares in Q4 2023, an estimated $132K.
  • Ascension Capital Advisors first reported a position in Pacific Biosciences in Q3 2023 and held it in 1 quarter.
  • Ascension Capital Advisors's Pacific Biosciences position peaked at $132K in Q3 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Ascension Capital Advisors's 13F filing for Q4 2023, filed 26 Jan 2024.